Birth defects risk appears low with newer-generation antiepileptics
First-trimester exposure to antiepileptic drugs compared with no exposure does not appear to increase the risk of major birth defects, according to a Danish study, published in the May 18 issue of the Journal of the American Medical Association.
First-trimester exposure to antiepileptic drugs compared with no exposure does not appear to increase the risk of major birth defects, according to a Danish study, published in the May 18 issue of the Journal of the American Medical Association.
Researchers studied 1,532 infants exposed to lamotrigine, oxcarbazepine, topiramate, gabapentin, or levetiracetam during the first trimester of pregnancy. Forty-nine of these infants were diagnosed with a major birth defect compared with 19,911 infants who were not exposed to an antiepileptic drug. Specifically, a major birth defect was diagnosed in 38 of 1,019 infants exposed to lamotrigine; in 11 of 393 infants exposed to oxcarbazepine; and in 5 of 108 infants exposed to topiramate. Of the 59 infants exposed to gabapentin and the 58 exposed to levetiracetam, 1 and 0 infants were diagnosed with birth defects, respectively.
The researchers note that epilepsy during pregnancy is a therapeutic challenge. Although the number of newly approved antiepileptic drugs has substantially increased since the 1990s, the data on first-trimester use of the newer-generation of therapeutic agents and birth defects are limited.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
